2022 AANP DIAGNOSTIC SLIDE SESSION CASE 5

NICOLE BECKER, MD

UNIVERSITY OF IOWA

MARGHERITA MILONE, MD PHD

MAYO CLINIC

KARRA A. JONES, MD PHD

DUKE UNIVERSITY

CLINICAL PRESENTATION

- 60-year-old woman
- Admitted to the hospital with severe generalized weakness and progressive dyspnea leading to acute respiratory failure requiring intubation
- History of delayed motor milestones and scoliosis since childhood
- Physical exam
 - Facial and neck flexor weakness
 - Limb weakness: proximal in the upper limbs and both proximal and distal in the lower limbs
 - Pes cavus
 - Contractures of wrists and ankles
- EMG showed evidence of a severe diffuse myopathy with fibrillation potentials only in the vastus medialis
- CK value was normal
- Left biceps muscle biopsy performed







DISCUSSION

DIFFERENTIAL DIAGNOSIS? ADDITIONAL STUDIES?



Slow myosin (type I fibers)



• Fast myosin (type 2 fibers)



Modified Gomori Trichrome





• Toluidine blue, Epon thick sections

Electron microscopy



Electron microscopy



ADDITIONAL HISTORY

• Genetic testing performed after the muscle biopsy identified a heterozygous pathogenic missense variant in *TPM3*



Congenital nemaline myopathy due to pathogenic missense variant in TPM3

CONGENITAL NEMALINE MYOPATHY

- One of the most common forms of congenital myopathy
 - Most common presentations: typical (infantile) and severe (neonatal) onset
- Typical/infantile onset presents with hypotonia, muscle hypotrophy, and generalized weakness of neck flexors and proximal limb muscles in infancy
 - Muscle weakness causes feeding and breathing difficulties
 - Disease course is typically mildly progressive or non-progressive
- Severe/neonatal onset presents in utero or at birth with inability to move or breathe
 - Also presents with joint contractures and fractures
- Mild onset is a less common presentation and presents in childhood or adulthood
 - Adult presentation must be distinguished from HIV-associated or sporadic late onset nemaline myopathy (SLONM)

CONGENITAL NEMALINE MYOPATHY

- Pathogenic variants in 12 genes identified as causes of nemaline myopathy
 - Involved with formation and regulation of the thin filament in the sarcomere
- NEB (nebulin) and ACTA1 (skeletal muscle alpha actin) are most commonly mutated genes
 - Other structural genes: *TPM3* (alpha tropomyosin), *TPM2* (beta tropomyosin), *MYPN* (myopalladin), *TNNT1* (troponin T1), and *TNNT3* (troponin T3)
 - Regulatory genes: *KLHL40, KLHL41, LMOD3, KBTBD13,* and *CFL2*



CONGENITAL NEMALINE MYOPATHY

- Histopathologic examination demonstrates nemaline rods aggregating in the cytoplasm
 - Rods commonly directly beneath the sarcolemma
 - Intranuclear rods less common
 - May have cap-like appearance on H&E stain
 - Rods most frequently aggregate in type 1 fibers
 - Presence in type 1 and type 2 fibers suggest pathogenic variants in *NEB* or *TNNT3*
- Rods appear red/purple on modified Gomori trichrome stain
- They immunoreact for alpha-actinin
- Electron microscopy demonstrates electron dense rods or ovoid structures in parallel with longitudinal sarcomeres with internal honeycomb structure





TPM3-RELATED NEMALINE MYOPATHY

TPM3 encodes alpha-tropomyosin

- Expressed in skeletal muscle, but only type 1 fibers
- Involved in actin filament coating and reveal of myosin binding sites
- *TPM3* pathogenic variants can cause autosomal dominant or more rarely autosomal recessive congenital myopathy
- *TPM3*-related congenital myopathy can lead to nemaline myopathy, cap myopathy, congenital fiber type disproportion or have overlapping pathologic features
- <10% of nemaline myopathy cases are due to pathogenic variants in *TPM3* or *TPM2*
 - *TPM3* pathogenic variants have been identified in both severe/neonatal onset and mild/childhood onset types

ACQUIRED NEMALINE MYOPATHY

- Associated with underlying monoclonal protein (SLONM) or HIV infection
- Most common presentation is dyspnea, proximal limb and axial muscle weakness, and muscle atrophy
- Progression to respiratory failure is a common cause of death
- Muscle biopsy demonstrates nemaline rods filling atrophic type 1 and 2 fibers without a type 1 fiber predominance
- Inflammatory component consisting of macrophages, T-lymphocytes, and MHC Class I expression on the sarcolemma has been observed in some SLONM cases
- Important to distinguish from congenital nemaline myopathy as SLONM has treatment options, including IVIg, chemotherapy, and autologous stem cell transplant

REFERENCES

- Laitila J, Wallgren-Pettersson C. Recent advances in nemaline myopathy. Neuromuscul Disord. 2021 Oct;31(10):955-967. PMID: 34561123.
- 2. Naddaf E, Milone M, Kansagra A, Buadi F, Kourelis T. Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes. Neurology. 2019;93(3):e298-305. PMID: 31167932
- 3. Nicolau S, Liewluck T, Tracy JA, Laughlin RS, Milone M. Congenital myopathies in the adult neuromuscular clinic: Diagnostic challenges and pitfalls. Neurol Genet. 2019 Jun 4;5(4):e341. PMID: 31321302
- Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A, Stenzel W, Rushing EJ, Van Damme P, et al. Sporadic lateonset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. Orphanet J Rare Dis. 2017 May 11;12(1):86. PMID: 28490364
- Tanboon J, Uruha A, Arahata Y, Dittmayer C, Schweizer L, Goebel H-H, Nishino I, Stenzel W. Inflammatory features in sporadic late-onset nemaline myopathy are independent from monoclonal gammopathy. Brain Pathol. 2021 May;31(3):e12962. PMID: 34043258